US Pharma MarketingLook out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s disease.
Four years after gaining FDA approval for Auvelity to treat major depressive disorder, Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with Alzheimer’s disease.
Source: FiercePharma